| (210) | Number of the EPO application | 17832646 |
| (220) | Filing date of the EPO application | 2017.12.21 |
| (80) | EPO patent specification publication (B) | EPB nr. 32/2021, 2021.08.11 |
| (110) | EPO patent number | 3558955 |
| (21) | Number of the application | e 2019 1237 |
| (71) | Name(s) of applicant(s), code of the country | AMGEN INC., US; |
| (72) | Name(s) of inventor(s), code of the country | LANMAN Brian Alan, US;
CEE Victor J., US;
PICKRELL Alexander J., US;
REED Anthony B., US;
YANG Kevin C., US;
KOPECKY David John, US;
WANG Hui-Ling, US;
LOPEZ Patricia, US;
ASHTON Kate, US;
BOOKER Shon, US;
TEGLEY Christopher M., US; |
| (73) | Name(s) of owner(s), code of the country | AMGEN INC., US; |
| (54) | Title of the invention | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 275/04 (2006.01.01); C07D 417/04 (2006.01.01); C07D 471/08 (2006.01.01); C07D 513/04 (2006.01.01); C07D 487/10 (2006.01.01); C07D 487/04 (2006.01.01); C07D 239/80 (2006.01.01); C07D 471/04 (2006.01.01); C07D 401/04 (2006.01.01); C07D 403/04 (2006.01.01); A61K 31/428 (2006.01.01); A61K 31/429 (2006.01.01); A61K 31/437 (2006.01.01); A61K 31/517 (2006.01.01); A61K 31/519 (2006.01.01); A61K 31/498 (2006.01.01); A61K 31/4985 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.12.31 |
| (30) | Priority | 201662438334 P, 2016.12.22, US |
| (86) | International application | PCT/US2017/067801, 2017.12.21 |
| (87) | International publication | WO 2018/119183, 2018.06.28 |